𝛼SK or Search

ENTITY

PegBio (2565 HK)

36

Analysis

Health Care • China

PegBio Co., Ltd. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, particularly metabolic disorders. The company develops differentiated therapeutics for conditions such as type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. PegBio was founded in 2008 and is headquartered in Hangzhou, Zhejiang Province, China.

more

Refresh

Exchange Announcement • 23 Sep 2026 16:49

2026 Interim Report

Exchange Announcement • 18 Sep 2026 22:27

Change In Use Of Proceeds From The Global Offering

Exchange Announcement • 18 Sep 2026 22:23

Proposed Change Of Auditor

Exchange Announcement • 02 Sep 2026 17:00

Voluntary Announcement Joint R&D Collaboration With Sn Bioscience Advancing The Long-Acting Development Of Three Next-Generation Innovative Peptide Candidates For Metabolic Diseases, Including Apgp6

Exchange Announcement • 25 Aug 2026 16:30

Announcement Of Interim Results For The Six Months Ended June 30, 2026

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x